Amgen's postmenopausal osteoporosis drug wins FDA panel backing

An advisory panel to the U.S. Food and Drug Administration on Wednesday recommended Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture, saying the benefits of the drug outweighed its risks.